Open Access Opinion Article ID: JVI-7-137

    Considerations to accelerating and maximize the preclinical studies to a safe and effective COVID-19 vaccine

    Reynaldo Oliva-Hernández*

    The emergence of novel coronavirus-2019 (COVID-19) by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and its rapid spread across the world have triggered a global health emergency without preceding. From the first report of COVID-19 at Wuhan city of China in December 2019 until today there has been an outbreak of COVID-19 around the world, with 97, 831, 595 confirmed cases and 2, 120, 877 death cases [1,2] and this number keeps growing.


    Published on: Jan 25, 2021 Pages: 1-3

    Full Text PDF Full Text HTML DOI: 10.17352/jvi.000037
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JVI